PTO/SS/96 (12-05)
Approved for use through 97/31/2005, OMB 9851-8931
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pagement Reduction Act of 1995, no persons are required to respond to a collection of information unless it depists a valid QMB control number. STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner: Avanta Ebarna S.A. Filed/issue Date: October 22, 1899 Application No /Patent No /Control No.: 19/425.742 COMPOSITIONS FOR TOPICAL APPLICATION HAVING ANDREGENIC ACTIONS Entitled: , a Franch corporation Aventis Pharma S.A. (Type of Assignee: corporation, portnership, university, government eigency, sto.) (Marrie of Assismes) states that it is: 1. The assignos of the entire right, title, and interest; or 2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is \_\_\_\_\_%) in the patent application/patent identified above by virtue of either; A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_\_, Frame \_\_\_\_\_\_ or a true popy of the original assignment is attached. OR B.[47] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: To: Norther Marion Coursed Democrat The document was recorded in the United States Patent and Trademark Office at Real 01044 Frame 0434 or for which a copy thereof is attached. <u> Précher Hadin Preserve Denosaliez To Alteries Phiema</u> 2, Prom: , The document was recorded in the United States Palent and Trademark Office at \_\_\_\_, or for which a copy thereof is attached. CHANG Frame Child \_, or for which a copy thereof is attached. \_\_\_, Frame \_\_\_\_<u>CALZA</u> Additional documents in the phain of title are listed on a supplemental sheet. As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 OFR Part 3, to record the assignment in the records of the USPTO. See MPEP The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. Telephone Number Printed or Typed Name

This obligation of information is required by \$7 CPR 3.73(b). The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CPR 1.11 and 1.14. This objection is estimated to take 12 minutes to complete, including gethering, preparing, and automating the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form endor suggestions for reducing this burden, should be sent to the Chief information Office. U.S. Patent and Theodorack Office. U.S. Department of Commerce, P.C. Box 1450, Alexandria, VA 22313-1458. DO NOT SEND FREE OR DOMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1458.

## Supplemental Sheet to Statement Under 37 CFR 3.73(B)

Application No.: 09/425,742

Filed: October 22, 1999

## B. Chain of Title

4. From: Sanofi-Aventis Deutschland GmbH To: Aventis Pharma S.A.
The document was recorded in the United States Patent and Trademark Office at

Recl: <u>017627</u> Frame: <u>0328</u>.